ArticleClinical and experimental immunology2002
Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis.
Article in Clinical and experimental immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Calcitriol Reduces the Inflammation, Endothelial Damage and Oxidative Stress in AKI Caused by Cisplatin.International journal of molecular sciences · 2022Article
- Novel Immune Cell Subsets Exhibit Different Associations With Vascular Outcomes in Chronic Kidney Disease Patients-Identifying Potential Biomarkers.Frontiers in medicine · 2021Article
- IL-10 from dendritic cells but not from T regulatory cells protects against cisplatin-induced nephrotoxicity.PloS one · 2020Article
- Protective effect and mechanism of IL-10 on renal ischemia-reperfusion injury.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis.Experimental and therapeutic medicine · 2018Article
- Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis.Nature communications · 2017Article
- Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery.Journal of the American Society of Nephrology : JASN · 2015Article
- 5-Lypoxygenase products are involved in renal tubulointerstitial injury induced by albumin overload in proximal tubules in mice.PloS one · 2014Article
- Principles for valid histopathologic scoring in research.Veterinary pathology · 2013Review
- The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations.European journal of pediatrics · 2011Review
- Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Renal dendritic cells ameliorate nephrotoxic acute kidney injury.Journal of the American Society of Nephrology : JASN · 2010Article
- Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis.Journal of the American Society of Nephrology : JASN · 2008Article
- Interleukin-10 promoter polymorphism is associated with the predisposition to the development of IgA nephropathy and focal segmental glomerulosclerosis in Korea.Journal of Korean medical science · 2005Article
- Effects of chemokines on proliferation and apoptosis of human mesangial cells.BMC nephrology · 2004Article
- Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway.The American journal of pathology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conflicting reports exist regarding the effects of interleukin-10 (IL-10) on mesangial cells. There have been reports of both proliferative and antiproliferative effects, and both proinflammatory and anti-inflammatory effects of IL-10 on mesangial cells. However, the potential for IL-10 to affect glomerulonephritis characterized by mesangial proliferation is not known. To test the hypothesis that IL-10 would limit experimental mesangial proliferative glomerulonephritis, IL-10 was administered to rats in which mesangial proliferative glomerulonephritis was induced by administration of anti-Thy 1 antibody. Compared to control treated rats, IL-10 treated rats showed less proliferation, with fewer cells in glomeruli. Glomerular cellular proliferation was reduced, assessed by the numbers of cells within glomeruli expressing either proliferating cell nuclear antigen (PCNA) or bromodeoxyuridine. Glomerular macrophage influx (but not the proportion of glomerular macrophages that were PCNA positive) was reduced by IL-10 administration. There was no significant reduction in glomerular alpha-smooth muscle actin staining. IL-10 treatment resulted in reduced renal IL-1beta mRNA expression and reduced glomerular ICAM-1 expression, but renal expression of MCP-1 and osteopontin mRNA was unaltered. This study demonstrates that in experimental mesangial proliferative glomerulonephritis IL-10 diminishes inflammatory cell recruitment and mesangial cell proliferation. The effects of IL-10 in inhibiting mesangial cell proliferation are likely to be due to a combination of direct effects of IL-10 on mesangial cells and effects mediated by macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.